
19 Jul, 2023 Phase 1 Results of Zilebesiran Published in the New England Journal of Medicine
Results from the Phase 1 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension, were published in the New England Journal of Medicine (NEJM).